These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 1531463)

  • 1. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?
    Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho J; Varela C
    Metabolism; 1997 Aug; 46(8):902-7. PubMed ID: 9258272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
    De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
    Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion.
    Lanzone A; Fulghesu AM; Guido M; Fortini A; Caruso A; Mancuso S
    Fertil Steril; 1992 Aug; 58(2):296-301. PubMed ID: 1321739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
    Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.